Navigation Links
Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain
Date:5/18/2009

akthrough bleeding attributed to DMPA. The reporting of adverse events decreased by 50% in the post treatment period; no pattern of specific safety concerns due to elagolix have been identified. Hot flashes were reported by approximately 40% of subjects during the screening period (mean 0.4 per day) and 40% during the treatment period (mean 0.7 per day). Approximately 25% of subjects reported hot flashes during the post-treatment period (mean 0.4 per day). No pattern of excessive estradiol suppression was detected.

The twelve-month data from the Petal Study will be presented at various upcoming scientific meetings and in manuscript form. The bone data from the Petal Study are scheduled for presentation at the Endocrine Society Meeting in Washington, DC on June 12, 2009. The Petal Study safety and efficacy data have been submitted for the American Society for Reproductive Medicine (ASRM) meeting scheduled this fall in Atlanta. A subset of the Petal Study subjects will return for Week 72 DXA scans and clinical assessments to satisfy earlier arrangements made in consultation with the FDA.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine related diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause a
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2009 Financial Results
2. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
3. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
4. Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
5. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
6. Coalition for Pulmonary Fibrosis Announces Awards and Activities at ATS International Conference
7. GNAX/AtlantaNAP Announces Newest Client, Health Information Designs
8. AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
9. AMR Research Announces Final Agenda for Sold-Out Supply Chain Executive Conference
10. International Student Insurance Announces Website Redesign
11. Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 DMG Productions announces the ... to broadcast on Monday, August 25, 2014 at 7:00 ... , In this episode, Innovations will go behind-the-scenes ... and improves human performance. Audiences will be amazed by ... spaces by installing and providing access to real musical ...
(Date:8/21/2014)... Raleigh, NC (PRWEB) August 21, 2014 ... proteins produced by Staph bacteria has been used to ... just posted an article on the new research. ... at the University of Western Australia treated mesothelioma ... that it killed the cancer cells while simultaneously stimulating ...
(Date:8/21/2014)... San Luis Obispo, CA (PRWEB) August 21, 2014 ... July/August edition of Current Pedorthics, a bi-monthly publication of the ... the field of pedorthics. , Bunion Bootie ... as an alternative solution for bunion sufferers and their pain. ... be worn in nearly any shoe to eliminate the friction ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 According to a ... Academy of Ophthalmology, environmental factors may outweigh genetics in the ... 42 percent of the world’s population is nearsighted, and this ... , “This is an important finding in the field ... “Not only are we finding better ways to treat ...
(Date:8/21/2014)... Beverly Hills Medical Center of Kuwait is excited to ... a new diagnostic option for measuring tear production levels to ... TearLab is a revolutionary new testing method for dry ... amount of tears a patient produces and take the necessary ... Director at the Kuwait medical center. “The test collects a ...
Breaking Medicine News(10 mins):Health News:Announcing New Episode Airing of Innovations on Monday August 25, 2014 via Discovery Channel 2Health News:Study Finds Bacteria Compound Shrinks Mesothelioma Tumors, According to Surviving Mesothelioma 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 3Health News:Study Suggests Environmental Factors May Outweigh Genetics When It Comes to Myopia 2Health News:Beverly Hills Kuwait is the First Medical Center in Kuwait with Access to TearLab 2
... ON, Sept. 17 /PRNewswire-FirstCall/ - AlphaRx Inc. ... to developing the next,generation of therapeutic products ... candidate, Streptomycin nanoparticles,will be the subject of ... in,Treatment and Pathogenesis of Mycobacterial Infections" at ...
... Company Serves as a Free Resource to Employees Seeking Senior ... ... the nation,s largest,referral service of senior care options, was recently recognized in ... to when an,employer does not offer eldercare assistance as a part of ...
... genes can work in more powerful and sneaky ways than ... JAK that is closely related to a common cancer-causing gene ... manner. JAK disrupts the activity of an organisms DNA on ... on in an embryos development. , A team from the ...
... Hotel, Washington, D.C.,National and International Health Care Professionals will Convene to ... ... Failure Patients, WASHINGTON, Sept. 17 ... convenes Sunday, September,16, 2007 at the Marriott Wardman Park Hotel in ...
... out of 4 Slept Better on New Sleep Better(TM) ... effort to test the,connection between a new, quality bed ... townspeople of Pillow, Pa. let go of one of ... Sleep Better(TM),Project. Residents of this central Pennsylvania bedroom ...
... 16, 2007 New findings by UT Southwestern Medical ... interferes with the beneficial effects estrogen has on the ... between cholesterol and estrogen in heart disease. , The ... October issue of the journal Nature Medicine , ...
Cached Medicine News:Health News:AlphaRx To Present at 47th Annual ICAAC 2Health News:A Place for Mom, Nation's Largest Senior Care Referral Service, Fills a Gap in Employee Benefits 2Health News:If you think cancer genes are simple, you don't know JAK 2Health News:If you think cancer genes are simple, you don't know JAK 3Health News:If you think cancer genes are simple, you don't know JAK 4Health News:If you think cancer genes are simple, you don't know JAK 5Health News:Heart Failure Society of America 11th Annual Scientific Meeting to Focus on Heart Failure Guidelines, Innovation and New Research 2Health News:Heart Failure Society of America 11th Annual Scientific Meeting to Focus on Heart Failure Guidelines, Innovation and New Research 3Health News:Pillow, PA's Great American Sleep Better(TM)Project Reports Results 2Health News:Pillow, PA's Great American Sleep Better(TM)Project Reports Results 3Health News:Cholesterol byproduct blocks heart health benefits of estrogen 2Health News:Cholesterol byproduct blocks heart health benefits of estrogen 3
(Date:8/21/2014)... 2014 InfinityQS International, Inc., the global ... , today announces Infusion Chicago, its 9 th ... held Oct. 9-10, 2014, at the Chicago Marriott ... the necessity for implementing a quality system that ... to gain insight into production processes. Complimentary registrations ...
(Date:8/21/2014)... , Aug. 21, 2014 CVS Caremark Corporation (NYSE: ... applicable Reference Yields and consideration payable in connection with its ... August 7, 2014 for (1) any and all of its ... and (2) up to a maximum amount of its 6.125% ... 5.750% Senior Notes due 2017 (collectively, the "Maximum Tender Offer ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Bedrocan Cannabis ... three independent members to its Board of Directors, ... experience of the company, a leading licensed producer ... . Internationally, Bedrocan has 13 years, experience in ... in seven countries, including Canada. ...
Breaking Medicine Technology:InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3
... REGENSBURG, Germany, June 2 The TGF-beta 2,inhibitor ... good safety,and tolerability in the systemic treatment of ... administered,intravenously, showed a clear proof of concept. Patients ... for seven days every other week,as second or ...
... Transplant Congress in Toronto, MIAMI, June 2 ... Departments of Surgery and Pathology at the University ... corroborated the value of,monitoring cell- mediated immunity (CMI) ... regular laboratory assay of cell function,(ImmuKnow(R)/Cylex). Their paper, ...
Cached Medicine Technology:Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma 2Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma 3Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma 4University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 2University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 3University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: